2529 |
How to Manage Complex SFA Lesions |
Seung-Whan Lee |
Apr. 20. 15 |
2528 |
Japanese Experience with Zilver PTX |
Hiroyoshi Yokoi |
Apr. 20. 15 |
2527 |
Optimizing Duration of Anti-platelet Therapy Following ACS |
Freek W.A. Verheugt |
Apr. 20. 15 |
2526 |
PLATO: Impact on the Management of ACS and Personalizing Treatment with Ticagrelor |
Gregg W. Stone |
Apr. 20. 15 |
2525 |
Zilver PTX 5-year Data: What Does It Mean to Clinical Practice? |
Mark W. Burket |
Apr. 20. 15 |
2524 |
Is Even Lower Even Better?: An Evidence Based Discussion |
Ki Hoon Han |
Apr. 20. 15 |
2523 |
Optimal Treatment in Femoropopliteal with Misago |
Seung-Woon Rha |
Apr. 20. 15 |
2522 |
Current EVT Market in Japan and Case Review of Misago |
Yoshinori Tsubakimoto |
Apr. 20. 15 |
2521 |
Final Answer RESTORE |
Jung-Min Ahn |
Apr. 20. 15 |
2520 |
EVT for Femoro-popliteal Diseases with Misago Stent: 2-yaer Outcomes in the Real-world 88 Patients |
Shuichi Seki |
Apr. 20. 15 |